RE:RE:RE:RE:Reds comment on keeping shareholders informed
Redbaron2211 wrote: So many I can not begin to list. I will agree with DF that I make assumptions however I feel they are rational. The recent success of this company backs them up to a certain extent.
Anyways the data coming out of these trials is not hope. My thesis is based on management's previous successes/experience and the data.
I do agree with the premise of this negativity however I feel it's more important to be looking at who to add rather than who to take away.
Red,
Lets be clear , it's not Toleikis but the science and Witowski and the early clinical results that have given hope this investment . And what dies Toleikis do with that success last two times ? I give him credit he's brought it this far , but he is out of his element . No pharma deals last five years . Several Collaborations whereby the management suddenly went into another direction. Poor IR and Ray Matthews and his friends costantky Selling into any news or private placement coming .
what management successes ? Witiowski's success thats it . Philip gets credit for arranging the trial after his first failure with Shapiro that ended up in a lawsuit whereby Shspiro copied the patents to the pouch .
The fear is Tolekis drives this into the ditch because he has no business sense to take it to the next level . Any further clinical trials with immune coating for type one diabetes will cost up to $100 million dollars potentially. An Fda clearance for Brittle diabetics alone will use up the $30 million in a heartbeat . Toleikis has not been able to close a pharma deal so far, we need a collaboration with a major pharma partnership to have enough funds to see this to reality.
These are not assumptions but facts.
Sally